Two cases of infections due to multidrug-resistant Bacteroides fragilis group strains

Journal of Clinical Microbiology

Volumn 44, Issue 9, 2006, Pages 3465-3467

  Katsandri, Anastasia ^a,c   Papaparaskevas, Joseph ^c   Pantazatou, Angeliki ^a   Petrikkos, Georgios L ^b   Thomopoulos, Georgios ^a   Houhoula, Dimitra P ^c   Avlamis, Athina ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFOXITIN; CIPROFLOXACIN; CLINDAMYCIN; ERTAPENEM; FLUCONAZOLE; GENTAMICIN; IMIPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TIMENTIN; TOBRAMYCIN;

AGED; ANAEROBIC BACTERIUM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES FRAGILIS; CASE REPORT; GRAM NEGATIVE INFECTION; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RARE DISEASE; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; BACTEROIDES FRAGILIS; BACTEROIDES INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS;

BACTEROIDES FRAGILIS;

EID: 33748806594     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00316-06     Document Type: Article

References (19)

1. Arpin, C., V. Dubois, A.-M. Rogues, F. Menard, A.-M. Gavinet, J.-P. Maire, J.-P. Gachie, M.-C. Bezian, and C. Quentin. 2002. Cross-infection due to imipenem-resistant Bacteroides fragilis associated with a totally implantable venous port. J. Clin. Microbiol. 40:3032-3034.
2. Brazier, J. S., S. L. J. Stubbs, and B. I. Duerden. 1999. Metronidazole resistance among clinical isolates belonging to the Bacteroides fragilis group; time to be concerned? J. Antimicrob. Chemother. 44:580-581.
3. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement, M100-A15. Clinical and Laboratory Standards Institute, Wayne, Pa.
4. Diniz, C. G., L. M. Farias, M. A. Carvalho, E. R. Rocha, and C. J. Smith. 2004. Differential gene expression in a Bacteroides fragilis metronidazole-resistant mutant. J. Antimicrob. Chemother. 54:100-108.
5. Gal, M., and J. S. Brazier. 2004. Metronidazole resistance in Bacteroides spp. carrying nim genes and the selection of slow-growing metronidazole- resistant mutants. J. Antimicrob. Chcmother. 54:109-116.
6. Hedberg, M., and C. E. Nord on behalf of the ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. 2003. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin. Microbiol. Infect. 9:475-488.
7. Jousimies-Somer, H. R., P. Summanen, D. M. Citron, E. J. Baron, H. M. Wexler, and S. M. Finegold. 2002. Advanced identification methods, p. 81-132. In H. R. Jousimies-Somer, P. Summanen, D. M. Citron, E. J. Baron, H. M. Wexler, and S. M. Finegold (ed.), Wadsworth-KTL anaerobic bacteriology manual, 6th ed. Star Publishing Company, Belmont, Calif.
8. Kato, N., K. Yamazoe, C.-G. Han, and E. Ohtsubo. 2003. New insertion sequence elements in the upstream region of cfiA in imipenem-resistant Bacteroides fragilis strains. Antimicrob. Agents Chemother. 47:979-985.
9. Koeth, L. M., C. E. Good, P. C. Appelbaum, E. J. C. Goldstein, A. C. Rodloff, M. Claros, and L. J. Dubreuil. 2004. Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J. Antimicrob. Chemother. 53:1039-1044.
10. Lofmark, S., H. Fang, M. Hedberg, and C. Edlund. 2005 Inducible metro-nidazole resistance and nim genes in clinical Bacteroides fragilis group isolates. Antimicrob. Agents Chemother. 49:1253-1256.
11. National Committee for Clinical Laboratory Standards. 2004. Methods for antimicrobial testing of anaerobic bacteria, 6th ed. Approved standard M11-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. Oteo, J., B. Aracil, J. I. Alos, and J. L. Gomez-Garces. 2000. High prevalence of resistance to clindamycin in Bacteroides fragilis group isolates. J. Antimicrob. Chemother. 45:691-693.
13. Redondo, M. C., M. D. Arbo, J. Grindlinger, and D. R. Snydman. 1995. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin. Infect. Dis. 20:1492-1496.
14. Snydman, D. R., N. V. Jacobus, L. A. McDermott, R. Ruthazer, E. J. C. Goldstein, S. M. Finegold, L. J. Harell, D. W. Hecht, S. G. Jenkins, C. Pierson, R. Venezia, J. Rihs, and S. L. Gorbach. 2002. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997-2000. Clin. Infect. Dis. 35:S126-S134.
15. Soki, J., R. Edwards, U. Edit, E. Fodor, Z. Beer, and E. Nagy. 2004. Screening of isolates from faeces for carbapenems-resistant Bacteroides strains; existence of strains with novel types of resistance mechanisms. Int. J. Antimocrob. Agents 24:450-454.
16. Teng, L. J., P. R. Hsueh, J. C. Tsai, S. J. Liaw, S. W. Ho, and K. T. Luh. 2002. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan. Antimicrob. Agents Chemother. 46:2908-2913.
17. Trinh, S., and G. Reysset. 1996. Detection by PCR of the nim genes encoding 5-nitroimidazole resistance in Bacteroides spp. J. Clin. Microbiol. 34:2078-2084.
18. Turner, P., R. Edwards, V. Weston, A. Gaziz, P. Ispahani, and D. Greenwood. 1995. Simultaneous resistance to metronidazole, co-amoxiclav, and imipenem in clinical isolate of Bacteroides fragilis. Lancet 345:1275-1277.
19. Wareham, D. W., M. Wilks, D. Ahmed, J. S. Brazier, and M. Millar. 2005. Anaerobic sepsis due to multidrug-resistant Bacteroides fragilis: microbiological cure and clinical response with linezolid therapy. Clin. Infect. Dis. 40:67-68.